Related Experiment Video
Updated: Jun 19, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Vascular remodeling after coronary stent implantation
Insights
First-generation drug-eluting stents (DES) reduce restenosis but raise concerns for late stent thrombosis due to delayed healing. Next-generation DES aim to improve safety and efficacy through optimized design and novel technologies.
Area of Science:
- Cardiovascular Medicine
- Biomaterials Science
- Interventional Cardiology
Background:
- Drug-eluting stents (DES) are standard for symptomatic coronary artery disease, significantly reducing restenosis compared to bare-metal stents (BMS).
- First-generation DES are linked to delayed stent healing, poor endothelialization, and persistent fibrin, increasing the risk of late stent thrombosis (LST).
- Risk factors for LST include complex lesion characteristics and hypersensitivity reactions.
Purpose of the Study:
- To review the challenges associated with first-generation DES, particularly late stent thrombosis.
- To explore the advancements in next-generation DES development.
- To highlight the need for further evaluation of novel DES technologies.
Main Methods:
- Review of pathological findings in patients with late DES thrombosis.
- Analysis of risk factors contributing to late stent thrombosis.
- Overview of emerging technologies in next-generation DES design.
Main Results:
- Pathologic studies reveal delayed healing and poor endothelialization with first-generation DES compared to BMS.
- Specific clinical scenarios increase the risk of late stent thrombosis.
- Next-generation DES focus on optimizing stent platform, polymer, and drug delivery.
Conclusions:
- While first-generation DES improved restenosis rates, concerns regarding late stent thrombosis persist.
- Novel approaches in next-generation DES, including biodegradable materials and polymer-free systems, aim to enhance stent healing and reduce thrombosis.
- Extensive preclinical and clinical evaluation is crucial to establish the safety and efficacy of future DES.
Abstract:
Drug eluting stents (DES) have significantly reduced restenosis when compared to BMS and are considered the standard of care in the treatment of symptomatic coronary artery disease. However, late stent thrombosis has emerged as a major concern with the use of first generation DES. Pathologic studies of patients dying from late DES thrombosis (first generation sirolimus-eluting stents and paclitaxel-eluting stents) showed that DES are associated with delayed healing characterized by poor endothelialization of stent struts and persistence of fibrin as compared to BMS. Additional risk factors for LST include long lesions, left main coronary artery, bifurcation stenting, ruptured plaques, and hypersensitivity reactions. Currently, the next generation DES are being developed to optimize the three major components of DES: the stent platform, the polymer coating and the drug. New technologies include biodegradable polymers and stents, polymer free drug delivery and prohealing approaches. Further preclinical testing and evaluation through large clinical trials are needed to determine the safety and efficacy of future DES in clinical practice.